AstraZeneca PLC
ZEGA
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
94,300
Stocks News & Analysis
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.00 | 21.50 | -0.24% |
| CAC 40 | 8,237.43 | 25.93 | 0.32% |
| DAX 40 | 24,892.20 | 23.51 | 0.09% |
| Dow JONES (US) | 49,462.08 | 484.90 | 0.99% |
| FTSE 100 | 10,122.73 | 118.16 | 1.18% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,547.17 | 151.35 | 0.65% |
| Nikkei 225 | 52,258.57 | 259.51 | -0.49% |
| NZX 50 Index | 13,699.26 | 35.68 | 0.26% |
| S&P 500 | 6,944.82 | 42.77 | 0.62% |
| S&P/ASX 200 | 8,700.40 | 23.10 | -0.26% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |